Professor Chuxia Deng has long focused on cancer and precision medicine, especially research on the carcinogenic mechanisms of BRCA1. He also covers metabolic diseases, aging, stem cells, organoids, tumor immunity, and drug development. He has published a series of pioneering research results in Cell, Nature, Science and their sub-journals, as well as various high-level journals. In total, he has published more than 500 papers, with over 88,000 citations, and a Google Scholar H-index of 158. His academic influence ranks first or second in the field of biochemistry in the Greater China region according to Elsevier (2023-2025). Since 2006, Professor Deng has served as the founding editor-in-chief of International Bioscience, which will have an IF of 11.7 in 2025.

1. Study of tumor mechanisms

2. Strategies to predict and overcome cancer drug resistance

3. Research on personalized cancer treatment based on tumor drug sensitivity testing

Education：

Sept 1986 - May 1992, University of Utah, USA, Molecular Biology, PhD

Feb 1982 - Dec 1984, Institute of Hydrobiology, Chinese Academy of Sciences, Genetics, MS Degree

Mar 1978 - Jan 1982, West-China Normal University, Biology, BS Degree

Professional Experience：

Jul 2026 - Present, Tenured Research and Teaching Chair Professor, School of Synthetic Biology, Shenzhen Institute of Technology

Dec 2020 - Jun 2026, Macau University - Ministry of Education Frontiers in Precision Oncology Science Center, Chief Scientist

Dec 2014 - Jun 2026, Faculty of Health Sciences, University of Macau, Dean, Director of Oncology Center, Chair Professor

Jun 1995 - Nov 2014, National Institutes of Health, USA, National Institute of Diabetes, Digestive and Kidney Diseases, Researcher

Jul 1992 - May 1995, Harvard Medical School, Howard Hughes Medical Institute, Postdoctoral Fellow

Sept 1984 - Sept 1986, Institute of Hydrobiology, Chinese Academy of Sciences, Assistant Researcher

Invited Talks and Academic Leadership：

1. Invited Speaker at AACR Annual Meeting 2019

Invited by John D. Carpten, Chair of the 2019 AACR Annual Meeting Program Committee, and Elizabeth M. Jaffe, AACR President, as one of three main seminar speakers.

Talk: "SIRT1 downstream targets in carcinogenesis"

Date: April 2, 2019 | Location: Atlanta, GA, USA

2. Organizer of the Macau Biomedical Science Symposium (2014–2026)

Organized 12 sessions of the symposium from 2014 to 2026, served as Chair for all 12 conferences, and gave invited talks at 5 of them. This annual symposium has become a key biomedical exchange platform in the Guangdong-Hong Kong-Macao Greater Bay Area.

3. Recent Invited Talks (since 2021)

Since 2021, participated in over 40 conferences and delivered talks. Representative conferences (in reverse chronological order):

1) 14th International Breast Cancer Stem Cell Summit (2025, Chongqing)

2) 4th Guangdong-Hong Kong-Macao Greater Bay Area (Shenzhen) International Regenerative Medicine Conference (2025, Shenzhen)

3) 9th Fatty Liver and Cancer Seminar & International Conference on Fatty Liver and Cancer (2024, Hefei)

4) 19th Society of Chinese Bioscientists in America (SCBA) International Symposium (2024, Guiyang)

5) Organoid and Organ-on-a-Chip Technology Application and Prospects Summit Forum & National Tour on Expert Consensus for Clinical Application of Tumor Organoid Drug Sensitivity (2024, Guangzhou)

6) 2023 Guangdong-Hong Kong-Macao Greater Bay Area International Oncology Forum & 3rd MD Anderson Cancer Center and Sino-American Joint Academic Annual Meeting (2023, Online)

7) Shenzhen International Conference on Safety and Health Testing (2023, Shenzhen)

8) International Symposium on Cryobiology and Biobank of Biological Samples (2023, Changsha)

9) 12th International Breast Cancer Stem Cell Summit Forum (2023, Kunming)

10) Fujian-Hong Kong-Macau-Taiwan Integrative Oncology Seminar (2023, Fuzhou)

11) 4th Workshop on Global Health (WGH2023) (2023, Beijing)

12) Global Anti-Cancer Collaboration Group Annual Meeting & 7th Clinical Trial Workshop (2022, Guangzhou)

13) China Pearl River International Conference (2022, Shenzhen)

14) Post-Meeting of the San Antonio Breast Cancer International Conference & Guangdong Medical Association Youth Academic Seminar on Breast Diseases (2021, Guangzhou)

15) 10th China Breast Cancer Stem Cell Summit Forum (2021, Kunming)

16) China-US Ophthalmology Research Collaboration Summit (2021, Guangzhou)

Awards and Honors

- 2024 Macau Natural Science Second Prize

Project: "Precision Oncology: From Research on Breast Cancer-Related Gene 1 (BRCA1) to Clinical Application"

Recipients: Deng Chuxia; Chen Qiang; Miao Kai; Sun Heng

- 8th Outstanding Achievement Award in Breast Cancer Research

Awarded at the 14th China Breast Cancer Research Conference (2025)

Technology Transfers:

(1) Chuxia Deng; Zonggen Peng; Fangyuan Shao; Hu Li; A buffer solution, kit, and proteasome detection method, 2024-03-19, China, ZL2022 1 1119256.5 (Patent)

(2) Chuxia Deng; Fuqiang Xing; Xiaojiao Li; Culture medium and method for cultivating gastrointestinal tumors using 3D tumor slice technology, 2025-02-24, China, ZL202411974863.9 (Patent)

Major Science and Technology Projects：

1. Macau Science and Technology Development Fund, Key R&D Program。 FDCT-0009/2022/AKP, Exploring effective methods and clinical applications for inhibiting cancer metastasis and drug resistance. 2023 to 2026

2. Macao Science and Technology Development Fund, Joint Project with the Ministry of Science and Technology, 0092/2020/AMJ, Translational study on enhancing protein damage by inhibiting proteasome activity to overcome breast cancer drug resistance, 2021 to 2024

3. Shenzhen Science and Technology Innovation Committee, Category C, SGDX20201103092601008, Developing a technology to overcome broad-spectrum cancer drug resistance by enhancing chemotherapy drug sensitivity, 2021 to 2023

4. National Natural Science Foundation of China (NSFC): 82030094, Identify cancer driver mutations in triple-negative breast cancer for development of effective therapies. Natural Science Foundation of China (NSFC): 82030094, 2021 to 2025

Representative Publications:

1. Zhang·Cuiting; Zhou·Jing-Bo; Lei·Josh Haipeng; Ang·Irene Ling; Miao·Kai; Xu·Xiaoling; Poon·Terence Chuen Wai; Cheung·Edwin; Chu-Xia Deng. Tumor cell intrinsic dsRNA innate immune response triggered by PARP inhibitor is compromised in BRCA1 deficient breast cancer by repressing IRF3. 2026. Protein & Cell, Jan 10:pwaf104. PMID: 41520145. IF: 18.2

2. Wang Y, Deng M, Lei H, Miao K, Shu X, Li J, Tang D, Feng Y, Su SM, Li L, Wang Y, Sun H, Shao F, An T, Li X, Zhou F, Xiang T, Xu X, Chu-Xia Deng. Lars2-signaling mediates platinum resistance by accumulating cancer stem cell population and suppressing anti-tumor immunity. 2026. Mar:85:101330 Drug Resist Updat. PMID: 41344104. IF: 22

3. Shao F, Li Z, Ran M, Chen Y, Liu J, Li B, Hong M, Si Q, Ye X, Chu X, Hou Y, Cheung E, Tam KY, Xiao H, Gao GF, Xu X, Deng CX. Low dose radiation induces new protein synthesis that promotes cancer radiotherapy resistance. 2026. Drug Resist Updat. Drug Resist Updat. 2026 May;86:101386. PMID: 41844504 IF: 22

4. Li·Ling; Feng·Yangyang; Zhou·Jingbo; Shao·Fangyuan; Peng·Yuzhong; Zang·Sitian; Lei·Josh Haipeng; Sun·Heng; Tang·Dongyang; Lin·Shiqi; Chen Jinghong; Li Hanghang; Chu Xiangpeng; Qiao Yunfeng; Guo Xinyu; Wu Kakun; Xu Xiaoling; Deng Chu-Xia; Proteasomes suppress anticancer drug-induced cytotoxicity by inhibiting mitochondrial protein import and promoting ROS-BNIP3-mediated mitophagy. Drug Resistance Updates, Nov;83:101294. PMID: 40882451 IF: 22

5. Shao F, Li Z, Xiao H, Chen Y, Zhang Y, Li L, Peng Y, Li X, Hou Y, Li B, Chu X, Ran M, Tang D, Han X, Yao J, Zhang C, Wang L, Li H, Shao N, Miao K, Xu X, Shi Y, Zhang C, Yan J, Lin Y, Chu-Xia Deng. Suppressing Protein Damage Response to Overcome Multidrug Resistance in Cancer Therapy. 2025. Cell Discov. Sep 30;11(1):80. PMID: 41027888 IF: 16.9

6. Tang D, Lin S, Zhou J, Lei JH, Shao F, Sun H, Chu X, Li L, He L, Qiao Y, Xu X, Chu-Xia Deng Augment proteasome inhibitor efficacy activates CD8+ T cell-mediated antitumor immunity in breast cancer. 2025. Cell Report Medicine. Jul 15;6(7):102211. PMID: 40609539 IF: 14

7. Kai Miao, Aiping Zhang, Xiaodan Yang, Yipeng Zhang, Anqi Lin, Lijian Wang, Xin Zhang, Heng Sun, Jun Xu, Jingyao Zhang, Yuzhao Feng, Fangyuan Shao, Sen Guo, Zhihui Weng, Peng Luo, Dong Wang, Shuai Gao, Xiao-Yang Zhao, Xiaoling Xu, Chu-Xia Deng. Lymphatic system is the mainstream for breast cancer dissemination and metastasis revealed by single-cell lineage tracing. 2025. Molecular Cancer. PMID: 40075470 2025, 24(1) IF: 42.2

8. Chen·Ping, Zhou·Jing-Bo, Chu·Xiang-Peng, Feng·Yang-Yang, Zeng·Qi-Bing, Lei·Josh-Haipeng, Wong·Ka-Pou, Chan·Tai-Ip, Lam·Chon-Wa, Zhu·Wen-Li, Chu Wai-Kuok, Hu Feng, Luo Guang-Hui, Chan Kin-long, Chu-Xia Deng. Establishing a cryopreserved biobank of living tumor tissues for drug sensitivity testing, Bioactive Materials, 2025, 46: 582-596 PMID: 40061435. IF: 23.6

9. Hyun-Seok Kim, Athanassios Vassilopoulos, Rui-Hong Wang, Tyler Lahusen, Zhen Xiao, Xiaoling Xu, Cuiling Li, Timothy D. Veenstra, Bing Li, Hongtao Yu, Junfang Ji, Xin Wei Wang, Seong-Hoon Park, Yong I. Cha, David Gius,5 and Chu-Xia Deng. SIRT2 Maintains Genome Integrity and Suppresses Tumorigenesis through Regulating APC/C Activity. Cancer Cell 2011. IF: 56.1

10. Hyun-Seok Kim, Cuiying Xiao, Rui-Hong Wang, Tyler Lahusen, Xiaoling Xu, Athanassios Vassilopoulos, Guelaguetza Vazquez-Ortiz, Won-Il Jeong, Ogyi Park, Sung Hwan Ki, Bin Gao, and Chu-Xia Deng. Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. Cell Metabolism, 2010. IF: 37

11. Rui-Hong Wang, Kundan Sengupta, Cuiling Li, Hyun-Seok Kim, Liu Cao, Cuiying Xiao, Sangsoo Kim, Xiaoling Xu, Yin Zheng, Beverly Chilton, Rong Jia, Zhi-Ming Zheng, Ettore Appella, Xin Wei Wang, Thomas Ried, and Chu-Xia Deng. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell, 2008.

IF: 56.1

12. Xiaoling Xu, Wenhui Qiao, Steven P. Linke, Liu Cao, Wen-Mei Li, Priscilla A. Furth, Curtis C. Harris, and Chu-Xia Deng. Genetic interactions between tumor suppressors Brca1and p53 in apoptosis, cell cycle and tumorigenesis. Nature Genetics 2001. IF: 25.5

13. Xiaoling Xu, Kay-Uwe Wagner, Cuiling Li, Anthony Wynshaw-Boris, Lothar Hennighausen and Chuxia Deng. Conditional mutation of BRCA1 in mammary glands results in abnormal ductal morphogenesis and tumor formation. Nature Genetics, 1999 IF: 25.5

14. Chuxia Deng, Pumin Zhang, J. Wade Harper, Stephen J. Elledge, Philip Leder. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell, 1995, IF: 45.1